Antiangiogenic Factors in Gastric Cancer

October 16, 2012 updated by: Jun Ho Lee, National Cancer Center, Korea

The Role of Endogenous Antiangiogenic Factors in Gastric Cancer Progression

Endogenous antiangiogenic factors are related with gastric cancer progression.

Study Overview

Status

Completed

Conditions

Detailed Description

Gastric cancers have been known to secrete the proangiogenic cytokine VEGF in vitro and in vivo. Tumor VEGF expression is correlated with the severity of disease in patients with gastric cancer and some authors have suggested using circulating VEGF as a prognostic factor or tumor marker.In addition to producing proangiogenic cytokines, recent data demonstrate that tumors can produce antiangiogenic cytokine as well. It has been suggested that, in humans, the generation of antiangiogenic compounds in the presence of a primary tumor suppresses the growth of distant metastases. This phenomenon has been demonstrated in mice and in patients with clear cell renal cancer, breast cancer, and colorectal cancer. However, the presence of endogenous antiangiogenic cytokines in patients with gastric cancer has not been reported.

Study Type

Observational

Enrollment (Actual)

240

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Korea, Republic of
    • Geonggi-do
      • Goyang-si, Geonggi-do, Korea, Republic of, 410-0769
        • National Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Eligible patients will undergo subtotal or total gastrectomy with D2 lymph node dissection

Description

Inclusion Criteria:

  • Histologic diagnosis of gastric adenocarcinoma
  • No other forms of cancer therapy, such as chemotherapy or radiotherapy for at least 3 weeks before the enrollment in study
  • Performance status of 0, 1, 2 on the ECOG criteria
  • ASA class I, II
  • Patient compliance that allow adequate follow up
  • Informed consent from patient or patient's relative.

Exclusion Criteria:

  • Second primary malignancy
  • EMR (Endoscopic mucosal resection) indication
  • Laparoscopic gastrectomy
  • Radiologic or clinical evidence of metastasis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Relationship between antiangiogenic factor and tumor, node, metastasis
Time Frame: One year
One year

Secondary Outcome Measures

Outcome Measure
Time Frame
Overall survival, treatment failure
Time Frame: 5 years
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Cancer Center, Korea

Investigators

  • Principal Investigator: Jun Ho Lee, M.D., Ph.D, Gastric Cancer Branch, National Cancer Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2006

Primary Completion (Actual)

July 1, 2008

Study Completion (Actual)

January 1, 2012

Study Registration Dates

First Submitted

August 13, 2008

First Submitted That Met QC Criteria

August 14, 2008

First Posted (Estimate)

August 15, 2008

Study Record Updates

Last Update Posted (Estimate)

October 18, 2012

Last Update Submitted That Met QC Criteria

October 16, 2012

Last Verified

October 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NCCCTS 04-105

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe